Antibody‐drug conjugate MORAb‐202 exhibits long‐lasting antitumor efficacy in TNBC PDx models

The antibody‐drug conjugate (ADC) MORAb‐202, consisting of farletuzumab paired with a cathepsin B–cleavable linker and eribulin, targets folate receptor alpha (FRA), which is frequently overexpressed in various tumor types. MORAb‐202 was highly cytotoxic to FRA‐positive cells in vitro, with limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuuchi, Keiji, Rybinski, Katherine, Fulmer, James, Moriyama, Tomoyuki, Drozdowski, Brian, Soto, Allis, Fernando, Shawn, Wilson, Kerrianne, Milinichik, Andrew, Dula, Mary Lou, Tanaka, Keigo, Cheng, Xin, Albone, Earl, Uenaka, Toshimitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177789/
https://www.ncbi.nlm.nih.gov/pubmed/33756060
http://dx.doi.org/10.1111/cas.14898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177789/
https://www.ncbi.nlm.nih.gov/pubmed/33756060
http://dx.doi.org/10.1111/cas.14898

Ejemplares similares